Inclusion-Body Myositis (IBM)

Research

Researchers supported by MDA are studying the underlying mechanisms that cause inflammatory myopathies, the group of diseases to which inclusion-body myositis (IBM) belongs. There are multiple drugs in clinical trials for IBM.

• Arimoclomol increases the production of proteins that protect our cells from stress (called heat shock proteins).
• Follistatin is a protein that has the potential to increase muscle mass by inhibiting another protein called myostatin.  
• Bimagrumab is an antibody that inhibits the myostatin pathway responsible for limiting muscle size.

There are several clinical trials for IBM in development; please click on for more details.

See also Gene Therapy Success in IBM and Advances in Inclusion-Body Myositis.